Home / Research library / NAD+
NAD+: molecular data, studies & sources
A small human pilot study measured plasma and urine metabolites during an intravenous NAD infusion. It examined metabolite handling, not proof of an anti-aging benefit. Trials of NMN, nicotinamide riboside or other precursors are not interchangeable with studies of NAD itself.
Overview sources: PMID 31572171
Compiled by PeptideTech Editors · Sources checked · Selected bibliography, not a systematic review
Molecular formula, weight & structure
- Molecular formula (MF)
- C21H27N7O14P2
- Molecular weight (MW)
- 663.4 g/mol
- PubChem compound ID
- 5892
- Record title
- Nadide
The selected structure is oxidized nicotinamide adenine dinucleotide. NADH and NAD precursors such as NMN or nicotinamide riboside are different chemical identities; their trials are not evidence for direct NAD administration.
Source: PubChem CID 5892 · retrieved 2026-09-21
Chemical identifiers and source data
- IUPAC name
- [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate
- InChIKey
- BAWFJGJZGIEFAR-NNYOXOHSSA-N
- SMILES
- C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)([O-])OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O)O)O)C(=O)N
Identifiers
- PubChem CID
- 5892
- CAS Registry Number
- 53-84-9via ChemIDplus, EPA DSSTox, FDA GSRS
- FDA UNII
- 0U46U6E8UK
- ChEMBL ID
- CHEMBL1234613
- InChIKey
- BAWFJGJZGIEFAR-NNYOXOHSSA-N
Other names and development codes: NSC-20272
CAS numbers are published only from ChemIDplus, EPA DSSTox or the FDA Global Substance Registration System; UNII codes are confirmed in FDA GSRS by structure, sequence or exact name. Checked 2026-10-07.
Calculated molecular descriptors
| Monoisotopic (exact) mass | 663.1091 Da |
|---|---|
| Heavy atoms | 44 |
| Hydrogen-bond donors | 7 |
| Hydrogen-bond acceptors | 17 |
| Rotatable bonds | 11 |
| Topological polar surface area | 321.1 Ų |
| Calculated logP (Crippen) | -3.65 |
| Rings | 5 |
| Stereocenters | 10 |
| Formal charge | 0 |
Computed with RDKit from the published SMILES (Crippen logP, topological polar surface area). Calculated descriptors are not measured properties of a supplied batch.
US regulatory status & drug development
Drug development record (ChEMBL)
Harmonized drug-development record from ChEMBL. The highest clinical stage is the furthest stage reached, as recorded by ChEMBL; it can lag regulatory approvals, and it is not an approval of a research-supplier product.
- ChEMBL ID
- CHEMBL1234613
- Modality
- Small molecule
- Highest clinical stage
- Phase 2
- Record name
- NADIDE
Synonyms, codes and trade names
- Synonyms and development codes
- CO-I · DPN · NAD · Nadide · NSC-20272
Identity check: Identical standard InChIKey to the PubChem record. Source: ChEMBL CHEMBL1234613 (EMBL-EBI, CC BY-SA 3.0) · retrieved 2026-10-07
Registered clinical trials
Studies registered on ClinicalTrials.gov that list NAD+ as an intervention. Studies that only measure the molecule as a biomarker, or use it only as a comparator or background arm for another drug, are excluded. A registration describes a planned or completed protocol; it does not report a result. Active studies are listed first.
7 registered studies matched, 3 currently active or recruiting.
- By highest phase
- Phase 3 · 1Phase 2 · 1Early phase 1 · 1Not applicable · 4
- By registry status
- Completed · 3Active Not Recruiting · 1Not Yet Recruiting · 1Recruiting · 1Unknown · 1
| Study | Phase · status | Conditions | Sponsor · size |
|---|---|---|---|
| A Clinical Trial to Assess the Absorption, Safety, and Efficacy of an Oral Nicotinamide Adenine Dinucleotide (NAD+) Supplement in Healthy AdultsNCT07692633 · start 2026-08 · primary completion 2027-03 | Not applicableNot Yet Recruiting | NAD+ Bioavailability · NAD+ Safety · NAD+ Efficacy | Reus Research80 participants |
| Combination Gerotherapeutic Interventions for Healthspan ImprovementNCT07475546 · start 2025-07-23 · primary completion 2026-04 | Phase 3Active Not Recruiting | Healthspan Improvement · Aging · Longevity | AgelessRx30 participants |
| Absorption and Tolerability of Injectable Administration of Niagen®+, as Compared to NAD+NCT06919328 · start 2024-10-31 · primary completion 2025-04-30 | Not applicableRecruiting | Healthy Aging | Nutraceuticals Research Institute70 participants |
| Effectiveness of Qualia NAD+ Supplementation on Intracellular NAD LevelsNCT06505967 · start 2024-07-01 · primary completion 2024-08-29 | Not applicableCompleted | NAD+ Levels in the Blood | Qualia Life Sciences170 participants |
| IV Administration of ChromaDex's Niagen® as Compared to NAD+NCT06382688 · start 2023-11-13 · primary completion 2024-03-08 | Not applicableUnknown | Healthy Aging | Nutraceuticals Research Institute53 participants |
| Renewal-NAD+: A Study of Oral NAD+ and Its Multi-omic Impact in a Healthy CohortNCT07336836 · start 2022-02-23 · primary completion 2022-06-04 | Early phase 1Completed | Health Adult Subjects · Healthy Participants | BioNADrx Holdings, Inc. Bryleos60 participants |
| Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 SyndromeNCT04604704 · start 2021-01-28 · primary completion 2023-01-23 | Phase 2Completed | Covid19 · Long COVID-19 · Post-COVID-19 Syndrome | AgelessRx36 participants |
Registry check 2026-10-09 · Run this search on ClinicalTrials.gov
Human intervention studies
Selected studies in which participants received NAD+, with their indexed or reviewed study type. Check the original article for the formulation, population and controls. Studies that only measured the molecule, or used it as a comparator, are listed separately below and are not counted as intervention studies.
- Human pilot study Compound given to participants
A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD.
Grant R, Berg J, Mestayer R et al. · Frontiers in aging neuroscience · 2019
Small human pilot measuring NAD-related metabolites during infusion. It does not demonstrate clinical anti-aging efficacy.
PMID 31572171 · DOI: 10.3389/fnagi.2019.00257
Preclinical research, reviews & other publications
Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.
No additional matching publication was retained. The search links below allow further investigation; they are not evidence that a study exists.
NAD+ supplier sources
Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.
NAD+ for sale: compare prices, sizes and forms from every tracked supplier →
| Supplier | Recorded packages | Example source listing |
|---|---|---|
| Blank PeptidesUSD | 500mg Vial · 1000mg Vial2 recorded offers | 500mg Vial · $60.00Stale observation · Checked Sep 30, 2026Supplier listing, NAD+ 500mg Vial, Blank Peptides, opens in a new tab |
| American PeptidesUSD | 500mg Spray · 1000mg Vial · 500mg Vial3 recorded offers | 500mg Spray · $100.00Checked Nov 6, 2026Supplier listing, NAD+ 500mg Spray, American Peptides, opens in a new tab |
| Amino ClubUSD | 500mg Vial · 750mg Spray2 recorded offers | 500mg Vial · $69.99Stale observation · Checked Oct 14, 2026Supplier listing, NAD+ 500mg Vial, Amino Club, opens in a new tab |
| Nova Peptide SupplyUSD | 500mg Vial · 1000mg Spray · 1500mg Spray3 recorded offers | 500mg Vial · $79.99Checked Nov 6, 2026Supplier listing, NAD+ 500mg Vial, Nova Peptide Supply, opens in a new tab |
| Amino USAUSD | 1000mg Vial · 500mg Vial2 recorded offers | 1000mg Vial · $230.00Checked Nov 6, 2026Supplier listing, NAD+ 1000mg Vial, Amino USA, opens in a new tab |
| Cenexa LabsUSD | 500mg Vial1 recorded offers | 500mg Vial · $99.99Checked Nov 6, 2026Supplier listing, NAD+ 500mg Vial, Cenexa Labs, opens in a new tab |
| LA PeptidesUSD | 500mg Spray · 500mg Vial · 1000mg Vial3 recorded offers | 500mg Spray · $64.99Checked Nov 3, 2026Supplier listing, NAD+ 500mg Spray, LA Peptides, opens in a new tab |
Reference sources & further reading
- PubChem compound record 5892 — chemical identity and structure.
- ChEMBL drug record CHEMBL1234613 — development stage, mechanism and synonyms.
- FDA Global Substance Registration System: UNII 0U46U6E8UK — substance identity, names and codes.
- Wikipedia: Nicotinamide adenine dinucleotide — Background encyclopedia; not a primary clinical source.
The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.
Search for additional research
These links run searches; their results have not been individually reviewed and can include unrelated compounds.
Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.
Related research profiles
5-Amino-1MQ
C10H11N2+
159.21 g/mol · PubChem CID 950107
3 selected publications · 0 human intervention studies
FOXO4-DRI
C228H388N86O64
5358 g/mol · PubChem CID 167312269
4 selected publications · 0 human intervention studies
GHK-Cu
C14H23CuN6O4+
402.92 g/mol · PubChem CID 71587328
1 selected publication · 0 human intervention studies · 1 registered trial
Glutathione
C10H17N3O6S
307.33 g/mol · PubChem CID 124886
7 selected publications · 3 human intervention studies · 37 registered trials
Small molecule · highest stage: Phase 3
Humanin
C119H204N34O32S2
2687.2 g/mol · PubChem CID 16131438
1 selected publication · 0 human intervention studies
L-Carnitine
C7H15NO3
161.20 g/mol · PubChem CID 10917
8 selected publications · 0 human intervention studies · 40 registered trials
Small molecule · highest stage: Approved in at least one jurisdiction (ChEMBL phase 4)